Re2O in Daegu: layering in the dermis, and why embossing appears
Look for the best clinic for Re2O in Daegu and two words come up every time — how densely it is injected, and embossing. They are really the same subject, because Re2O goes shallow, into the dermis, divided across many points.
The short version
Re2O supplies extracellular matrix derived from human acellular dermal matrix (hADM) into the dermis. It is not a product that builds volume underneath — it leaves the skin’s own material in that layer. So the shallower it sits, the more likely you are to see embossing, the small raised beads visible right after treatment. That is usually not a failure but a sign the layer was right. This article is about which layer, and how the dose is divided.
Why density is the key word for this product
Filler is gathered in one place to build a shape. Re2O is the opposite. The target is dermal density, so the result is set by how evenly it is laid across an area. The same total volume placed in few points heavily and in many points lightly are two different treatments.
So “across how many points is it divided” is a more precise consultation question than “how many cc”. What depth is being targeted comes next.
What gets called “a feel for the needle” lives here too. Dermal thickness differs across the face. In a study measuring 30 fixed cadavers with a 3D scanner, facial skin was 2.1 ± 0.4 mm and superficial fat 5.2 ± 1.9 mm — a standard deviation of 36% of the mean. Injecting at a consistent depth therefore means changing where the needle stops, person by person and site by site.
Embossing — what those small beads mean
Embossing is the name for the small raised beads visible after treatment. Liquid entering the dermis briefly expands that layer, and this is what you see.
So embossing is closer to evidence the product reached the dermis. Conversely, skin that stays perfectly smooth raises the possibility that the material went deeper than intended. Deeper is not necessarily wrong, but it is a different plane from the one aimed at.
How fast embossing settles varies by area and by division. In our practice it is short where skin is thick, on the cheek and forehead, and around the eyes or on the neck the same volume shows for longer and more plainly. That is why, in thin areas, we reduce the volume and increase the points to begin with.
Where skin is thin, such as around the eyes, the same volume shows longer and more clearly. If you have something important in the diary, it is safer to set the treatment date around it.
Where the material comes from — to know first
hADM is matrix from donated human dermis with the cells removed. We tell you this origin before the decision, not after — choosing with it in hand is not the same as choosing without it. If it does not sit right with you, we do not press it. There are other classes for the same goal.
Regulation is also moving. The MFDS gave notice in July 2026 of an amendment to the Rules on Human Tissue Safety, and as of September 2026 it has not been promulgated. This is not written to recommend or discourage the class, but because it is information you need in order to decide.
Sessions and dose — how we set them
We set sessions by the state of the skin, not by the calendar. We start on three sessions a month apart and decide on more by how it has settled. We do not fix a package first and then fill it.
Dose is about division before it is about total. Because the target is dermal density, how many points the dose is divided across affects the result more than how many cc go in. We reduce the volume and increase the points in thin areas — around the eyes and on the neck.
And we give you a contact threshold. Pain in one spot lasting more than two days, a change in colour, or swelling that grows again means call us rather than wait.
Worth asking in consultation
- Across how many points it is divided — this sets the result more than the total.
- What depth is being targeted — it should differ by site.
- Whether embossing is explained beforehand — unexplained, it is mistaken for a complication.
- Which product the quoted figures belong to — the 175-completer trial is a product not sold here.
- Whether the origin of the material is stated first — matrix from donated human skin.
- The box and the vial — you can check them before treatment.
- What decides the next session — the calendar, or the skin.
How we judge it at Miso Clinic
We treat Re2O as a treatment aimed at dermal density, and nothing wider. If the goal is to restore lost volume, a product that works in a different plane is the right answer — because using a dermal product on a fat-layer problem is a design in the wrong plane.
We divide the injection densely and change the depth by site. With dermal thickness varying by 36% of the mean, we do not run the same hand across the whole face. And we explain embossing before treatment, not after — experiencing it knowingly and experiencing it as a surprise are entirely different things.
Which treatment suits you can differ with skin condition, how much change you want and what you have had before. We do not recommend treatments that are not needed.
Frequently asked questions
Does embossing mean something went wrong?
Usually the opposite. Liquid entering the dermis briefly expands that layer, so the beads are closer to evidence that the product reached the plane it was aimed at. Skin that stays perfectly smooth raises the possibility that it went deeper than intended.
How long does embossing last?
It varies by area and by division. It is short where skin is thick, on the cheek and forehead; around the eyes the same volume shows for longer and more plainly. So in thin areas we reduce the volume and increase the points. Embossing is usually not a failure but a sign the layer was right.
How many cc should I have?
Division comes before total. Because the target is dermal density, how many points the dose is divided across affects the result more than how many cc go in. We set volume and point count to the dermal thickness of the area, and reduce the volume where skin is thin.
How strong is the evidence for Re2O?
The human trial is small at 20 subjects over 20 weeks, but it is a split-face double-blind randomised design comparing the two sides of the same face. The paper does not name the product; identity was confirmed against trial registration number NCT07155278.
I heard the 175-patient trial had good results.
That trial used a Chinese product which is not distributed in Korea. Nasolabial improvement was 88.4% against 85.4% at three months and 70.9% against 69.7% at six months, holding up against a crosslinked collagen filler - but it is not Re2O's result. We have often seen those numbers used without distinguishing the products.
Is the material really human skin?
Yes. It is matrix from donated human dermis with the cells removed. That is why donation, processing, testing, storage and distribution are all recorded, and why safety is managed in layers: donor screening, viral inactivation and decellularisation. We tell you this before the decision.
How are sessions decided?
By the state of the skin, not the calendar. We start on three sessions a month apart and decide on more by how it has settled. We do not fix a package first and then fill it.
How do I check the product is genuine?
You may ask to see the box and the vial before treatment. We do that on request.
Further reading
Author and clinic
Written and reviewed by Lee Chi-Hak, MD, director of Miso Clinic, Daegu. The treatment standards and injection design here are the ones we use in practice.
4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu (Kyungpook National University Hospital station, exit 1)
+82 53-428-2700 · www.clinicmiso.co.kr
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.
← Clinical columns · Reference library · Miso Clinic Daegu
한국어 · English